Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer

被引：2

作者：

Maniakas, Anastasios ^{[1
,6
]}

Sullivan, Andrew ^{[1
]}

Hu, Mimi I. ^{[2
]}

Busaidy, Naifa L. ^{[2
]}

Cabanillas, Maria E. ^{[2
]}

Dadu, Ramona ^{[2
]}

Waguespack, Steven G. ^{[2
]}

Fisher, Sarah B. ^{[3
]}

Graham, Paul H. ^{[3
]}

Gross, Neil D. ^{[1
]}

Grubbs, Elizabeth G. ^{[3
]}

Perrier, Nancy D. ^{[3
]}

Wang, Jennifer R. ^{[1
]}

Gunn, Brandon ^{[4
]}

Garden, Adam S. ^{[4
]}

Megahed, Romy ^{[1
]}

Navuluri, Sriram ^{[1
]}

Li, Xu ^{[1
]}

Williams, Michelle D. ^{[5
]}

Zafereo, Mark ^{[1
,6
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Div Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2024年 / 46卷 / 02期

关键词：

locoregional control; medullary thyroid cancer; overall survival; postoperative radiation therapy; targeted therapy;

D O I：

10.1002/hed.27584

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundUse of postoperative radiation therapy (PORT) in locoregionally advanced medullary thyroid cancer (MTC) remains controversial. The objective was to evaluate the effect of PORT on locoregional control (LRC) and overall survival (OS).MethodsRetrospective cohort study of 346 MTC patients separated into PORT and no-PORT cohorts. Relative indications for PORT, as well as changes in patterns of treatment, were recorded.Results49/346 (14%) received PORT. PORT was associated with worse OS; adjusted HR = 2.0 (95%CI 1.3-3.3). PORT was not associated with improved LRC, even when adjusting for advanced stage (Stage III p = 0.892; Stage IV p = 0.101). PORT and targeted therapy were not associated with improved OS compared to targeted therapy alone; adjusted HR = 1.2 (95%CI 0.3-4.1).ConclusionsUse of PORT in MTC has decreased and its indications have become more selective, coinciding with the advent of effective targeted therapies. Overall, PORT was not associated with improved LRC or OS.

引用

页码：328 / 335

页数：8

共 50 条

[1] Reply to Letter to the Editor regarding "Decreased utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer"
Maniakas, Anastasios
Hu, Mimi I.
Gunn, G. Brandon
Zafereo, Mark
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (07): : 1848 - 1849
[2] Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer
Isobe, K
Uno, T
Kawakami, H
Ueno, N
Aruga, T
Yasuda, S
Hanazawa, T
Okamoto, Y
Ito, H
Shigematsu, N
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (03) : 116 - 120
[3] The Role of Radiation Therapy in the Treatment of Medullary Thyroid Cancer
Terezakis, Stephanie A.
Lee, Nancy Y.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (05): : 532 - 541
[4] Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma
Groen, Andries H.
Beckham, Thomas H.
Links, Thera P.
Goldman, Debra A.
Sherman, Eric J.
Tuttle, Michael M.
Bijl, Hendrik P.
Wong, Richard J.
Plukker, John Th. M.
Lee, Nancy Y.
Groen, Andries H.
Plukker, John Th. M.
Beckham, Thomas H.
Lee, Nancy Y.
Riaz, Nadeem
Tsai, Chiaojung J.
Yu, Yao
Links, Thera P.
Goldman, Debra A.
Zhang, Zhigang
Sherman, Eric J.
Tuttle, Michael M.
Shaha, Ashok R.
Wong, Richard J.
Bijl, Hendrik P.
JOURNAL OF SURGICAL ONCOLOGY, 2020, 121 (02) : 234 - 243
[5] Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
Matrone, A.
Prete, A.
Nervo, A.
Ragni, A.
Agate, L.
Molinaro, E.
Giani, C.
Valerio, L.
Minaldi, E.
Piovesan, A.
Elisei, R.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2021, 44 (10) : 2139 - 2151
[6] Evaluation of Survival and Postoperative Radiation Among Patients with Advanced Medullary Thyroid Carcinoma: An Analysis of the National Cancer Database
Ow, Thomas J.
Mehta, Vikas
Kim, Seokhwa
Vakil, Mayand
Friedmann, Patricia
In, Haejin
ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (04) : 2582 - 2591
[7] Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
A. Matrone
A. Prete
A. Nervo
A. Ragni
L. Agate
E. Molinaro
C. Giani
L. Valerio
E. Minaldi
A. Piovesan
R. Elisei
Journal of Endocrinological Investigation, 2021, 44 : 2139 - 2151
[8] Combination Therapy of Medullary Thyroid Cancer Using Radiation and Vandetanib
Sandblom, V.
Spetz, J.
Shubbar, E.
Swanpalmer, J.
Forssell-Aronsson, E.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S768 - S768
[9] Concurrent Cetuximab and Radiation Therapy in Patients with Locoregionally Advanced Head and Neck Cancer
Cheng, H. C.
Ngan, R. K. C.
Au, K. H.
HONG KONG JOURNAL OF RADIOLOGY, 2012, 15 (01): : 29 - 35
[10] Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
A. Matrone
A. Prete
A. Nervo
A. Ragni
L. Agate
E. Molinaro
C. Giani
L. Valerio
E. Minaldi
A. Piovesan
R. Elisei
Journal of Endocrinological Investigation, 2021, 44 : 2859 - 2859

← 1 2 3 4 5 →